What is HC Wainwright’s Estimate for DBVT Q1 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT) – HC Wainwright issued their Q1 2026 earnings estimates for shares of DBV Technologies in a research report issued to clients and investors on Friday, March 27th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS and FY2030 earnings at $1.75 EPS.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($1.15) EPS for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The company had revenue of $0.65 million during the quarter.

DBVT has been the topic of several other research reports. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Guggenheim reiterated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research note on Friday, March 27th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Citizens Jmp raised their target price on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, March 27th. Finally, Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and a consensus price target of $38.65.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $20.89 on Monday. The business’s fifty day moving average is $21.56 and its 200 day moving average is $17.48. DBV Technologies has a fifty-two week low of $5.75 and a fifty-two week high of $26.18. The company has a market capitalization of $1.16 billion, a PE ratio of -4.00 and a beta of -0.97.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ikarian Capital LLC bought a new position in shares of DBV Technologies in the 4th quarter valued at about $10,064,000. Vestal Point Capital LP purchased a new stake in DBV Technologies during the fourth quarter valued at approximately $5,751,000. Squadron Capital Management LLC purchased a new stake in DBV Technologies during the fourth quarter valued at approximately $4,601,000. Millennium Management LLC lifted its stake in shares of DBV Technologies by 89.7% in the 4th quarter. Millennium Management LLC now owns 640,885 shares of the company’s stock valued at $12,286,000 after purchasing an additional 303,022 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new stake in shares of DBV Technologies in the 4th quarter valued at approximately $479,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.